COPENHAGEN, Denmark and PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab have received approval of Arzerra (ofatumumab) from the FDA for CLL that is refractory to fludarabine and alemtuzumab.
Today, GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN - News) announced the accelerated approval of Arzerra(TM) (ofatumumab) from the U.S. Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab.
“The approval of Arzerra brings an important new treatment option to patients with refractory CLL,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “This approval also marks a key milestone for Genmab as it is our first antibody to reach the market. All of us involved in the development of Arzerra are pleased that we have been able to move the product so quickly through research and development and meet our goal of providing this innovative therapy to patients.”
The approval is based on results from a pivotal study in which 42% of patients with CLL who were refractory to both fludarabine and alemtuzumab (two therapies used in treating CLL) responded to treatment with Arzerra. These patients had a median duration of response of 6.5 months. The most common adverse reactions (greater than or equal to 10%) seen were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections. The most common serious adverse reactions seen were infections(including pneumonia and sepsis), neutropenia, and pyrexia.
“Arzerra is a significant step forward in helping patients and physicians better manage the challenges of refractory CLL. Patients now have a new choice,” said Kathy Rouan, Ph.D., Vice President and Medicines Development Leader at GlaxoSmithKline. “The Arzerra approval demonstrates the commitment of the GSK BioPharm and Oncology Units to developing new biopharmaceutical treatment options for cancer patients.”
Arzerra is a monoclonal antibody that causes the body’s immune response to fight against normal and cancerous B-cells. Arzerra attaches to the small and large loop epitopes -- on a molecule called CD20, which is found on the surface of B-cells, the type of cell which becomes cancerous in CLL.
The approval of Arzerra was supported by a positive recommendation by the FDA’s Oncologic Drugs Advisory Committee (ODAC) at ASCO on May 29, 2009, in which the panel voted, 10-3, that the Arzerra data were likely to predict clinical benefit for patients with CLL whose disease is refractory to fludarabine and alemtuzumab.
Arzerra is anticipated to be available for prescription use in the coming weeks.
GSK has added Arzerra to its expanding patient assistance program, Commitment to Access, and has expanded the program. This program assists eligible patients, with or without insurance, with paying for cancer medicines. For more information about the program, visit www.CommitmentToAccess.com or call 1-8ONCOLOGY1 (1-866-265-6491).
Conference Call
Genmab will hold a conference call to discuss today’s news on October 27, 2009, at
2:30 pm CEST 1:30 pm BST 9:30 am EDT
The conference call will be held in English.
The dial in numbers are as follows:
+1-877-941-8609 (in the US) and provide conference ID number 4171231
+1-480-629-9818 (outside the US) and provide conference ID number 4171231
To listen to a live webcast of the call please visit www.genmab.com.
The GSK Biopharm R&D Unit seeks to harness the therapeutic potential ofbiopharmaceuticals for the benefit of patients with debilitating and lifethreatening disease. We work in tandem with the Oncology R&D Unit, which is dedicated to producing innovations in cancer treatment that will make profound differences in the lives of patients. Through GSK’s revolutionary ‘bench to bedside’ approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector.
GlaxoSmithKline -- one of the world’s leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit www.genmab.com.
GSK Enquiries UK Media enquiries: Philip Thomson +44 20 8047 5502 Claire Brough +44 20 8047 5502 Stephen Rea +44 20 8047 5502 Alexandra Harrison +44 20 8047 5502 Gwenan White +44 20 8047 5502 US Media enquiries: Nancy Pekarek +1 919 483 2839 Kevin Colgan +1 919 483 2839 Mary A. Rhyne +1 919 483 2839 Sarah Alspach +1 919 483 2839 Ken Inchausti +1 919 483 2839 European Analyst/Investor enquiries: David Mawdsley +44 20 8047 5564 Sally Ferguson +44 20 8047 5543 Gary Davies +44 20 8047 5503 US Analyst/Investor enquiries: Tom Curry +1 215 751 5419 Jen Hill Baxter +1 215 751 7002
Cautionary statement regarding forward-looking statements for GSK: Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007.
Registered in England and Wales No. 3888792
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS
Forward Looking Statement for Genmab:
This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to ourbusiness area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM); HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM) and UniBod (R) are all trademarks of Genmab A/S. Arzerra(TM) is a trademark of GlaxoSmithKline.
Stock Exchange Release no. 39/2009
Contact:
Genmab A/S Helle Husted, Vice President, Investor Relations +45 33 44 77 30, Cell: +45 25 27 47 13 h.husted@genmab.com
